More information: Kobie Boshoff et al, The perceptions of Autistic school students of their well-being at school: a meta-synthesis, European Journal of Special Needs Education (2024). DOI: 10.1080 ...

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, ...

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline.

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.

Pfizer elevated Dr. Chris Boshoff, MD, PhD to serve as chief scientific officer as well as research and development president on Wednesday morning. Boshoff, who has been with Pfizer for more than 11 ...

Boshoff has also worked as Pfizer’s head of development in Japan and as chief development officer for oncology and rare disease. “Dr. Boshoff is the ideal leader to propel Pfizer’s R&D ...

In conjunction with Dr. Boshoff’s promotion, Roger Dansey, M.D., will serve as the Interim Chief Oncology Officer from January 1, 2025, and will support the search for a permanent appointee before his ...

“Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy, driving the delivery of additional ...

Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.

Pfizer (PFE) announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research ...

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.